← Data Explorer · All industries
Major group 28: Chemicals and allied products
Companies whose SIC industry code starts with 283. Companies with no code (SIC 0) and shell companies (SIC 9995) are left out.
Its 4-digit industries: 2833 Medicinal chemicals & botanical products · 2834 Pharmaceutical preparations · 2835 In vitro & in vivo diagnostic substances · 2836 Biological products, (no diagnostic substances)
The tiles, heatmap and tables below use the industry’s S&P 500 companies.
Average profit weight in the industry over time
The mean profit weight over every ordered pair of the industry’s companies, each quarter: S&P 500 companies (solid) and all companies (faded). Click a quarter to show it.
Computed from the current data release, using every firm in the sample. Published papers used earlier releases and samples, so their figures differ slightly.
Show the numbers
Profit weights between the 17 largest companies, 2020 Q4
Each cell is the profit weight of the row company’s shareholders on the column company (darker: higher). Companies are ordered so that tightly linked groups form blocks. Largest means most reported owners. Click a cell to compare the two companies.
Investors who drive it, 2020 Q4
The investors that contribute most to the industry’s average profit weight: roughly, those holding sizeable stakes in many of its companies at once. Owner types follow the forms each investor files with the SEC: 13F, Forms 3/4/5, 13D or 13G, in that order of precedence (an investor that files both 13F and Forms 3/4/5, such as Carl Icahn, counts as a 13F filer). Big Three is Vanguard, BlackRock and State Street.
- Big Three
- 13F filers
- 13G filers
- 13D filers
- Forms 3/4/5 filers
The companies, 2020 Q4
| Company | Reported owners | Reported ownership | SEC CIK | Report |
|---|---|---|---|---|
| Abbvie Inc SIC 2836 · S&P 500 | 2467 | 67.88% | 1551152 | |
| Amgen Inc SIC 2836 · S&P 500 | 2047 | 75.93% | 318154 | |
| Lilly Eli & Co SIC 2834 · S&P 500 | 1757 | 82.39% | 59478 | |
| Gilead Sciences Inc SIC 2836 · S&P 500 | 1483 | 77.96% | 882095 | |
| Zoetis Inc SIC 2834 · S&P 500 | 1345 | 91.02% | 1555280 | |
| Viatris Inc SIC 2834 · S&P 500 | 1157 | 77.03% | 1792044 | |
| Baxter International Inc SIC 2834 · S&P 500 | 1061 | 88.58% | 10456 | |
| Biogen Inc SIC 2836 · S&P 500 | 997 | 84.51% | 875045 | |
| Vertex Pharmaceuticals Inc SIC 2834 · S&P 500 | 914 | 91.99% | 875320 | |
| I D E X X Laboratories Inc SIC 2835 · S&P 500 | 907 | 87.28% | 874716 | |
| Regeneron Pharmaceuticals Inc SIC 2834 · S&P 500 · dual class | 845 | 86.98% | 872589 | |
| Alexion Pharmaceuticals Inc SIC 2836 · S&P 500 | 792 | 90.48% | 899866 | |
| Catalent Inc SIC 2834 · S&P 500 | 518 | 105.5% | 1596783 | |
| Incyte Corp SIC 2836 · S&P 500 | 497 | 93.18% | 879169 | |
| Tilray Inc SIC 2834 · S&P 500 · dual class | 208 | 35.48% | 1731348 | |
| Hookipa Pharma Inc SIC 2836 · S&P 500 · dual class | 71 | 67.30% | 1760542 | |
| Aligos Therapeutics Inc SIC 2836 · S&P 500 · dual class | 52 | 71.48% | 1799448 |
Something look wrong? Report a problem with this page. How to report.
These pages are for looking up individual companies and investors. Please don’t copy them with automated tools. If you need the full data, request a download: it is free of charge for academic research.